Prostate Cancer
November 19
3 min read
An exploratory biomarker analysis of the phase III TALAPRO-2 trial found that circulating tumor DNA burden and reductions in circulating tumor cells were associated with radiographic progression–free survival in patients with metastatic castration-resistant prostate cancer receiving talazoparib plus enzalutamide or enzalutamide alone.